Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconj... | Completed
Efficacy and Safety Study of Cyclos... | Completed
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis

Trial Source

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Atopic Conjunctivitis
Unfortunately contact details are not available for this trial.
Primary Contact Details
Completed
Recruitment Status
NCT00884585
Primary Trial ID Number

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye). The study consists of a double-masked phase, and open-labeled phase, and an open-labeled maintenance phase. For the first 3 months of the study, patients will receive either masked Cyclosporine 0.010% eye drops or vehicle four times daily; for the next 6 months, patients may receive open-labeled Cyclosporine 0.010% eye drops four times daily. At month 9, patients who are in remission, will be re-randomized to receive either open-labeled Cyclosporine 0.010% eye drops four times daily or twice daily.
Research Details
    Sorry, this information is not available
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : Cyclosporine Vehicle, Drug : Cyclosporine 0.010%

Study Arm Groups : Placebo followed by COS, Cyclosporine Ophthalmic Solution (COS) followed by COS, Placebo followed by COS

Intervention Type
See Interventions above
Primary Outcome Measures
    Percentage of Treatment Responders; Baseline, Month 2
Secondary Outcome Measures
    Percentage of Punctate Corneal Staining Responders; Month 2; Percentage of Patients With an Improvement in the Composite Symptom Score; Baseline, Month 2; Percentage of Patients With an Improvement in the Punctate Corneal Staining Score; Baseline, Month 2
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
12 Years - N/A
Who Can Participate
Patients
Number of Participants
Sorry, this information is not available
Participant Inclusion Criteria
    Inclusion Criteria:

    - Have a clinical diagnosis of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye)

    - Be on stable doses of your current AKC medications for at least 2 weeks

    Exclusion Criteria:

    - You have used contact lenses within 48 hours of Day 1 or think you may have to wear contact lenses during the study

    - You are pregnant, breastfeeding, or planning to become pregnant during the study

    - You have used a calcineurin inhibitors (e.g. topical tacrolimus or topical pimecrolimus) on or around your eyes including eyelids within 4 weeks
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Research Site
Newcastle upon Tyne
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Australia, Canada, Czech Republic, France, Germany, India, Israel, Italy, New Zealand, Spain, United Kingdom, United States
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Sorry, this information is not available
EudraCT Number
Not available for this trial
Funder(s)
    Sorry, this information is not available
Other Study ID Numbers
192371-016
Sponsor(s)
Allergan
Key Dates

Recruitment Start Date

May 2009

Recruitment End Date

Oct 2010

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date Assigned

17 Apr 2009

Last Updated

02 Nov 2012